BIOCYTOGEN PHARMA. H YC1 Asset Resilience Ratio
BIOCYTOGEN PHARMA. H YC1 asset resilience ratio. BIOCYTOGEN PHARMA. H YC1 (I54) has an Asset Resilience Ratio of 0.35% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can BIOCYTOGEN PHARMA. H YC1 fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BIOCYTOGEN PHARMA. H YC1 (2021–2023)
Asset resilience ratio of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2023. This chart shows how BIOCYTOGEN PHARMA. H YC1's Asset Resilience Ratio has changed over time. Read BIOCYTOGEN PHARMA. H YC1 balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BIOCYTOGEN PHARMA. H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIOCYTOGEN PHARMA. H YC1 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €8.62 Million | 0.35% |
| Total Liquid Assets | €8.62 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: BIOCYTOGEN PHARMA. H YC1 maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BIOCYTOGEN PHARMA. H YC1 Industry Peers by Asset Resilience Ratio
Compare BIOCYTOGEN PHARMA. H YC1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
BIOCYTOGEN PHARMA. H YC1 Asset Resilience Ratio by Year (2021–2023)
BIOCYTOGEN PHARMA. H YC1 asset resilience ratio by year from 2021 to 2023. The table below shows the annual Asset Resilience Ratio data for BIOCYTOGEN PHARMA. H YC1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.35% | €8.49 Million ≈ $9.92 Million |
€2.45 Billion ≈ $2.86 Billion |
+0.05pp |
| 2022-12-31 | 0.29% | €8.20 Million ≈ $9.58 Million |
€2.80 Billion ≈ $3.27 Billion |
-4.05pp |
| 2021-12-31 | 4.34% | €100.00 Million ≈ $116.91 Million |
€2.30 Billion ≈ $2.69 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more